We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stamp-Sized Microfluidic Chip Uses Programmed Magnetic Nanobeads and Off-the-Shelf Cellphone to Diagnose COVID-19

By LabMedica International staff writers
Posted on 26 Feb 2021
Print article
Image: Stamp-sized microfluidic chip (Photo courtesy of Jeff Fitlow)
Image: Stamp-sized microfluidic chip (Photo courtesy of Jeff Fitlow)
A new testing system uses programmable magnetic nanobeads, an off-the-shelf cellphone and a plug-in diagnostic tool to diagnose COVID-19 in 55 minutes or less.

Researchers at Rice University (Houston, TX, USA) have developed a stamp-sized microfluidic chip that measures the concentration of SARS-CoV-2 nucleocapsid (N) protein in blood serum from a standard finger prick. The nanobeads bind to SARS-CoV-2 N protein, a biomarker for COVID-19, in the chip and transport it to an electrochemical sensor that detects minute amounts of the biomarker. The researchers argue their process simplifies sample handling compared to swab-based PCR tests that are widely used to diagnose COVID-19 and need to be analyzed in a laboratory.

The new tool relies on a slightly more complex detection scheme but delivers accurate, quantitative results in a short amount of time. To test the device, the lab relied on donated serum samples from people who were healthy and others who were COVID-19-positive. According to the researchers, a longer incubation yields more accurate results when using whole serum. The lab found that 55 minutes was an optimum amount of time for the microchip to sense SARS-CoV-2 N protein at concentrations as low as 50 picograms (billionths of a gram) per milliliter in whole serum. The microchip could detect N protein in even lower concentrations, at 10 picograms per milliliter, in only 25 minutes by diluting the serum fivefold. Paired with a Google Pixel 2 phone and a plug-in potentiostat, it was able to deliver a positive diagnosis with a concentration as low as 230 picograms for whole serum.

A capillary tube is used to deliver the sample to the chip, which is then placed on a magnet that pulls the beads toward an electrochemical sensor coated with capture antibodies. The beads bind to the capture antibodies and generate a current proportional to the concentration of biomarker in the sample. The potentiostat reads that current and sends a signal to its phone app. If there are no COVID-19 biomarkers, the beads do not bind to the sensor and get washed away inside the chip. The researchers believe that it would not be difficult for industry to manufacture the microfluidic chips or to adapt them to new COVID-19 strains if and when that becomes necessary.

“What’s great about this device is that doesn’t require a laboratory,” said Peter Lillehoj, a mechanical engineer at Rice lab where the system was developed. “You can perform the entire test and generate the results at the collection site, health clinic or even a pharmacy. The entire system is easily transportable and easy to use.”

Related Links:
Rice University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more